Genomize and Genomenon Partner to Empower Researchers and Clinicians with Comprehensive Genomic Insights

ArticlesLeave a comment

“This strategic partnership aligns with both companies’ missions to streamline genomic analysis by delivering cutting-edge solutions that accelerate discoveries and clinical decision-making. By leveraging Genomenon’s powerful datasets, Genomize users will gain access to deeper variant interpretation capabilities, driving innovation in personalized medicine.” Integration of Mastermind and Cancer Knowledgebase (CKB) Data To Drive Unprecedented Efficiency in…

"Rare diseases'' may seem straightforward, affecting a small percentage of the population, although definitions of rarity differ globally. For instance, the U.S. defines these diseases as affecting fewer than 200,000 people, while the EU uses a prevalence criterion of fewer than 1 in 2,000. Additionally, rarity can be context-specific, varying across demographics and regions, emphasizing the intricate nature of these conditions.​

Are Rare Diseases Really Rare?

Articles

Rare diseases” may seem straightforward, affecting a small percentage of the population, although definitions of rarity differ globally. For instance, the U.S. defines rare diseases as affecting fewer than 200,000 people, while the EU uses a prevalence criterion of fewer than 1 in 2,000. Additionally, rarity can be context-specific, varying across demographics and regions, emphasizing the intricate nature of these conditions.